|
Video: What is a Stock Split?
|
|
Neurocrine Biosciences is applying its capabilities into neuroscience to develop medicines for neurology, neuroendocrinology and neuropsychiatry-related disorders and diseases. Co.'s commercially available medicines include INGREZZA®, which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 mg, 60 mg and 80 mg capsules); and ONGENTYS®, which is a once-daily, peripherally acting Catechol-O-methyltransferase inhibitor utilized to prolong the duration of effect of levodopa, the primary treatment option for Parkinson's disease patients, during periods of the day where the effects of levodopa wear off and motor symptoms worsen. According to our Neurocrine Biosciences stock split history records, Neurocrine Biosciences has had 0 splits. | |
|
Neurocrine Biosciences (NBIX) has 0 splits in our Neurocrine Biosciences stock split history database.
Looking at the Neurocrine Biosciences stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Neurocrine Biosciences shares, starting with a $10,000 purchase of NBIX, presented on a split-history-adjusted basis factoring in the complete Neurocrine Biosciences stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/24/2014 |
|
End date: |
04/22/2024 |
|
Start price/share: |
$13.79 |
|
End price/share: |
$133.66 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
869.25% |
|
Average Annual Total Return: |
25.49% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$96,908.38 |
|
Years: |
10.00 |
|
|
|
|
|